Clinical Trials Logo

Clinical Trial Summary

Pterygium is a disease associated with proliferation of the fibrovascular tissues of the conjunctiva into the cornea and is related to factors such as ultraviolet light exposure, chronic stimulation, inflammation, climate, and genetics.


Clinical Trial Description

The first line of treatment for primary pterygium is surgical excision, and despite postoperative adjuvant therapy using mitomycin C, cyclosporine, β-irradiation, argon laser, and bevacizumab, recurrence rates remain high . Mitomycin C is a metabolic inhibitor extracted from Streptomyces caespitosus that inhibits DNA synthesis . Cyclosporine is an immunosuppressant that selectively suppresses T-helper cells, controls interleukin synthesis and secretion, and inhibits vascular endothelial growth factor (VEGF) Bevacizumab is an anti-VEGF antibody that inhibits angiogenesis. Each agent has been studied as an adjuvant therapy to inhibit post-surgery pterygium recurrence. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05627947
Study type Interventional
Source Egymedicalpedia
Contact
Status Completed
Phase Phase 1
Start date January 1, 2021
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02641132 - Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count. Phase 4
Completed NCT02342392 - Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study Phase 2/Phase 3
Recruiting NCT01387971 - Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders N/A
Recruiting NCT05978687 - The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision Phase 4
Not yet recruiting NCT06042296 - Expression of CD44, PCNA and E-cadherin in Pterygium Tissue
Completed NCT04022811 - Effect of Bromfenac on Pain Related to Pterygium Surgery Phase 4
Recruiting NCT01261455 - Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia N/A
Recruiting NCT01249235 - Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery N/A
Completed NCT01115517 - Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery Phase 2
Completed NCT00768963 - Ranibizumab for the Inhibition of Neovascularization in Pterygia Phase 1
Completed NCT00949728 - Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia N/A
Recruiting NCT00563277 - Surgical Treatment of Concurrent Cataract and Primary Pterygium N/A
Completed NCT00346450 - Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Phase 3
Completed NCT03533244 - A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia Phase 2
Completed NCT04403516 - Dextenza in Pterygium Surgery Phase 4
Recruiting NCT02911532 - Tissue Engineering Conjunctiva for the Treatment of Pterygium and Atretoblepharia N/A
Not yet recruiting NCT03304366 - Corneal Changes With Pentacam Before and After Pterygium N/A
Unknown status NCT02015000 - Surgical Result of Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation N/A
Completed NCT00344201 - Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery Phase 1
Recruiting NCT00326560 - Comparison of Glue With Sutures for Pterygium Surgery Phase 3